Please do not leave this page until complete. This can take a few moments.
Immunotherapies. Vaccines. We’ve all had a crash course in these subjects during this year of the pandemic.
Now a Farmington startup is taking immunotherapies and vaccines in new directions in the battle against disease — including COVID-19.
Bijan Almassian is president and CEO at CaroGen Corp. His small team — five full-time employees and five part-timers — occupies space in UConn Health’s Cell and Genome Building on Farmington Avenue. But much of the firm’s research is going on in laboratories spread across several universities.
CaroGen’s lead product is an immunotherapy that targets Hepatitis B, a viral disease that affects the liver and is spread through bodily fluids. While there are Hep B vaccines on the market, the one CaroGen is working on is for treating chronic Hepatitis B, a disease that afflicts 240 million people worldwide.
The vaccine is in pre-clinical trials and has attracted a $5 million grant from the National Institutes for Health. Yale University and Albany Medical College are the research partners on the project.
CaroGen is also working on immunotherapies for ovarian cancer with researchers at Wayne State University in Detroit and for colorectal cancer with researchers at UConn.
Elsewhere, CaroGen is playing a role in the possible development of follow-up vaccines for COVID-19 variants.
The basis of CaroGen’s business is an immunotherapy concept developed by Dr. John Rose at Yale. CaroGen holds the exclusive rights to develop and commercialize the versatile virus-like vesicle (VLV) platform.
“It’s a long-term play,” explains Almassian.
Indeed. CaroGen become a portfolio company of Connecticut Innovations in 2013 and has scored some impressive grants since 2018. But it has generated zero dollars of revenue.
The business model calls for developing the pure science from proof of concept through the early stages of testing. However, when testing moves to the costly phased trials, CaroGen would seek to collaborate with a pharmaceutical company with the deep pockets necessary for drug development and marketing.
The road to a breakthrough product sale is a rocky one but Almassian sees the challenges clearly. He has experience developing other drugs as CEO of the now defunct Aria Neurosciences in Hamden. The firm had been working on pharmaceutical treatments for Alzheimer’s disease since 2008.
One of CaroGen’s largest challenges is access to capital.
“We wouldn’t have survived without Connecticut Innovations,” he said.
Still, he is frustrated by CaroGen’s inability to tap Connecticut’s private investor community.
At one low point, Almassian flew to China and raised $1 million. He contrasts that to the zero dollars he’s raised from investors within his home state.
Grants and research partners have bridged the gap so far. But CaroGen’s breakthrough moment isn’t here yet.
Almassian, an immigrant from Iran who holds a Ph.D. in medicinal chemistry from Massachusetts College of Pharmacy and Health Sciences and postdoctoral training in oncology at Boston University Medical School, remains confident.
“I’m building a company for the long haul,” he explains.
The Hartford Business Journal 2025 Charity Event Guide is the annual resource publication highlighting the top charity events in 2025.
Learn moreHartford Business Journal provides the top coverage of news, trends, data, politics and personalities of the area’s business community. Get the news and information you need from the award-winning writers at HBJ. Don’t miss out - subscribe today.
SubscribeDelivering Vital Marketplace Content and Context to Senior Decision Makers Throughout Greater Hartford and the State ... All Year Long!
Read HereThe Hartford Business Journal 2025 Charity Event Guide is the annual resource publication highlighting the top charity events in 2025.
Hartford Business Journal provides the top coverage of news, trends, data, politics and personalities of the area’s business community. Get the news and information you need from the award-winning writers at HBJ. Don’t miss out - subscribe today.
Delivering Vital Marketplace Content and Context to Senior Decision Makers Throughout Greater Hartford and the State ... All Year Long!
In order to use this feature, we need some information from you. You can also login or register for a free account.
By clicking submit you are agreeing to our cookie usage and Privacy Policy
Already have an account? Login
Already have an account? Login
Want to create an account? Register
In order to use this feature, we need some information from you. You can also login or register for a free account.
By clicking submit you are agreeing to our cookie usage and Privacy Policy
Already have an account? Login
Already have an account? Login
Want to create an account? Register
This website uses cookies to ensure you get the best experience on our website. Our privacy policy
To ensure the best experience on our website, articles cannot be read without allowing cookies. Please allow cookies to continue reading. Our privacy policy
0 Comments